- Home
- LFT vs LTRN Comparison
LFT vs LTRN Comparison
Compare LFT & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | LTRN |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 46.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LFT | LTRN |
|---|---|---|
| Price | $0.69 | $2.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 259.9K | 99.2K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 18.49% | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $668.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $1.11 |
| 52 Week High | $2.37 | $4.98 |
Technical Indicators
Market Signals| Indicator | LFT | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 25.49 | 42.63 |
| Support Level | N/A | $2.49 |
| Resistance Level | $1.40 | $3.67 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 12.71 | 48.76 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.